# Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct04171726` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04171726](<https://clinicaltrials.gov/study/NCT04171726>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04171726

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04171726. Allocation not applicable; no masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2023-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04171726, source copy `cardio:ctgov-nct04171726-2022-07-27`, retrieved 2026-10-26)
- Started: 2019-08-01 (actual) (ClinicalTrials.gov record NCT04171726, source copy `cardio:ctgov-nct04171726-2022-07-27`, retrieved 2026-10-26)
- Primary completion: 2023-06-01 (anticipated) (ClinicalTrials.gov record NCT04171726, source copy `cardio:ctgov-nct04171726-2022-07-27`, retrieved 2026-10-26)
- Completion: 2023-09-01 (anticipated) (ClinicalTrials.gov record NCT04171726, source copy `cardio:ctgov-nct04171726-2022-07-27`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT04171726, source copy `cardio:ctgov-nct04171726-2022-07-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04171726-2022-07-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation
- Acronym: REDOX-TAVI
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Edoxaban
- Lead sponsor: Erasmus Medical Center
- Lead sponsor class: OTHER
- Collaborator: Daiichi Sankyo
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry lists this organization as the lead sponsor: Erasmus Medical Center (`cardio:org-erasmus-medical-center`)
- Registry lists this organization as a collaborator: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

## Provenance

Content hash: a3d4825ba31bdcd9a4ac4819fb3bbebcd0007e81eeb5abf7decc074540c907fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
